Royalty Pharma agreed to invest in Neurimmune’s cliramitug, paying $125 million upfront for a 3% to 4% royalty plus additional payments tied to development and regulatory milestones. cliramitug is a TTR-fibril-depleting antibody being tested in the Phase III DepleTTR-CM trial, with results expected in 2028, as the ATTR-CM market continues to expand amid limited disease-modifying options.